SELECTION OF PHOSPHOLIPID AND METHOD OF FORMULATION FOR OPTIMUM ENTRAPMENT AND RELEASE OF LAMIVUDINE FROM LIPOSOME
The present investigation was aimed to compare various phospholipids and different methods that would be appropriate to produce liposomes having vesicle size in the range of 200-300 nm, PDI less than 0.500, maximum entrapment and delayed release of lamivudine. The phospholipids employed were Phospholipon® 90G, Phospholipon® 90H, 1,2-Dimyristoyl-sn-glysero-3-phosphocholine (DMPC) and 1,2-Dipalmitoyl-sn-glysero-3-phosphocholine (DPPC). They were used in various molar ratio with cholesterol and blank liposomes were prepared initially by thin film hydration and ether injection method. The thin film hydration method was only found to be appropriate to produce liposome of desired size and PDI. Hence, the molar ratios of employed phospholipids:cholesterol that produced liposomes as per the expected parameters was then used to load lamivudine. The method of preparation, phospholipid: cholesterol molar ratio, hydrations above transition temperature and hydration time were showed direct influence on vesicle size, PDI, percentage encapsulation and in-vitro release. Phospholipon® 90H: cholesterol: lamivudine in the molar ratio 1:2:1 produced liposomes having desired vesicle size and PDI with maximum drug entrapment and sustained release. The encapsulation efficiency of drug in liposomes was in the order of Phospholipon® 90H> Phospholipon® 90G > DPPC > DMPC.
Keywords: Liposomes, Lamivudine, Phospholipid, Thin film hydration method, Ether injection method, encapsulation efficiency
2. Gupta S, Vyas SP, Development and characterization of amphotericin B bearing emulsomes for passive and active macrophage targeting, J. Drug Target. 2007; 15(3):206-217.
3. Kumar L, Verma S, Prasad DN, Bhardwaj A, Vaidya B, Jain AK, Nanotechnology: A magic bullet for HIV AIDS treatment, Artif. Cells Nanomed. Biotechnol., 2015; 43(2):71-86.
4. Iannazzo D, Pistone A, Romeo R, Giofrè SV, Nanotechnology approaches for antiretroviral drugs delivery, J. Aids. Hiv. Infec., 2015;1(2):201. doi:10.15744/2454-499X.1.201
5. Sankar V, Madhura KL, Parmar N, Formulation and in-vitro evaluation of zidovudine-lamivudine nanoparticles, Ind. J. Pharm. Edu. Res., 2012; 46(2):192-196.
6. Wang B, Chen GQ, Mao ZW, Zhang YY, Yu DH, Gao CY, Preparation and cellular uptake of PLGA particles loaded with lamivudine, Chin. Sci. Bull., 2012; 57:3985-3993.
7. Tamizhrasi S, Shukla A, Shivkumar T, Rathi V, Rathi JC, Formulation and evaluation of lamivudine loaded polymethacrylic acid nanoparticles, Int. J. Pharm. Tech. Res., 2009; 1:411-415.
8. Jain S, Tiwary AK, Sapra B, Jain NK, Formulation and evaluation of ethosomes for transdermal delivery of lamivudine, AAPS PharmSciTech., 2007; 8(4):Article 111.
9. Pai RS, Devi KV, Lamivudine liposomes for transdermal delivery-formulation characterization, stability and in-vitro evaluation, Int. J. Pharm. Sci. Nanotech., 2009; 1(4):317-326.
10. Dutta T, Jain NK, Targeting potential and anti-HIV activity of lamivudine loaded mannosylated poly (propyleneimine) dendrimer, Biochim. Biophys. Acta., 2007; 1770:681-686.
11. Begum MY, Dasari S, Sudhakar M, Lakshmi BVS, Manga M, Development and evaluation of co-encapsulated stavudine and lamivudine niosomes for the controlled delivery, Der Pharmacia Sinica., 2014; 5(1):1-10.
12. Lim J, Chouai A, Lo ST, Liu W, Sun X, Simanek EE, Design, synthesis, characterization, and biological evaluation of triazine dendrimers bearing paclitaxel using ester and ester/disulfide linkages, Bioconjug. Chem., 2009; 20(11): 2154-2161.
13. Duncan R, Izzo L, Dendrimer biocompatibility and toxicity, Adv. Drug Deliv. Rev., 2007; 7(15):2215-2237.
14. Malik N, Wiwattanapatapee R, Klopsch R, Lorenz K, Frey H, Weener JW et. al., Dendrimers: relationship between structure and biocompatibility in-vitro and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo, J. Control Release, 2000; 65(1-2):133-148.
15. Namdeo A, Jain NK, Neosomes as drug carriers, Indian J. Pharm. Sci, 1996; 58(2):41-46.
16. Kumarn GP, Rajeshwarrao P, Nonionic surfactant vesicular systems for effective drug delivery-an overview, Acta Pharm. Sin. B., 2011; 1(4):208-219.
17. Mudshinge SR, Deore AB, Patil S, Bhalgat CM, Nanoparticles: emerging carriers for drug delivery, Saudi Pharm. J., 2011; 19:129-141.
18. Dwivedi C, Yadav R, Tiwari SP, Satapathy T, Roy A, Role of liposome in novel drug delivery system, Journal of Drug Delivery & Therapeutics, 2014; 4(2):116-129
19. Vishvakrama P, Sharma S, Liposomes: an overview, Journal of Drug Delivery and Therapeutics, 2014; Special Issue 1:47-55. https://doi.org/10.22270/jddt.v0i0.843
20. Zerin T, Rushmi ZT, Akter N, Mow RJ, Afroz M, Kazi M, Matas MD, Rahman M, Shariare MH, The impact of formulation attributes and process parameters on black seed oil loaded liposomes and their performance in animal models of analgesia, Saudi Pharm. J., 2017; 25:404-412.
21. Oussoren C, Magnani M, Fraternale A, Casabianca A, Chiarantini L, Ingebrigsten R et. al., Liposomes as carriers of the antiretroviral agent dideoxycytidine-5%-triphosphate, Int. J. Pharm., 1999; 180:261-270.
22. Poste G, Bucana C, Raz A, Bugelski P, Kirsh R, Fidler IJ, Analysis of the fate of systemically administered liposomes and implications for their use in drug delivery, Cancer Res., 1982; 42:1412-1422.
23. Herman EH, Rahman A, Ferrans VJ, Vick JA, Schein PS, Prevention of chronic doxorubicin cardiotoxicity in beagles by liposomal encapsulation, Cancer Res. 1983; 43:5427-5432.
24. Fidler IJ, Brown NO, Hart IR, Species variability for toxicity of free and liposome-encapsulated muramyl peptides administered intravenously, J. Biol. Response Mod., 1985; 4:298-209.
25. Mehta RT, Hopfer RL, McQueen T, Juliano RL, Lopez-Berestein G, Toxicity and therapeutic effects in mice of liposome-encapsulated nystatin for systemic fungal infections, Antimicrob. Agents Chemother., 1987; 31:1901-1903.
26. Shivhare UD, Ambulkar DU, Mathur VB, Bhusari KP, Godbole MD, Formulation and evaluation of pentoxyfylline liposome formulation, Dig. J. Nanomater. Biostruct., 2009; 4(4):857-862.
27. Elbialy NS, Mady M, Ehrlich tumor inhibition using doxorubicin containing liposomes, Saudi Pharm. J., 2015; 23:182-187.
28. Chopra S, Venkatesan N, Betageri GV, Liposomes as nanocarriers for anti-HIV therapy, Drug Deliv. Transl. Res., 2013; 3:471-478.
29. Chono S, Tauchi Y, Morimoto K, Influence of particle size on the distributions of liposomes to atherosclerotic lesions in mice, Drug Dev. Ind. Pharm., 2006; 32(1):125-135.
30. Chono S, Tanino T, Seki T, Morimoto K, Uptake characteristics of liposomes by rat alveolar macrophages: influence of particle size and surface mannose modification, J. Pharm. Pharmacol, 2007; 59(1):75-80.
31. Dubey V, Mishra D, Dutta T, Nahar M, Saraf DK, Jain N.K., Dermal and transdermal delivery of an anti-psoriatic agent via ethanolic liposomes, J. Control Release, 2007; 23:148-154.
32. Arora S, Prashar B, Dhamija H, Chandel A, Thakur V, Niosomes: the unique vesicular drug carriers, Journal of Drug Delivery & Therapeutics, 2012; 2(1):96-101. https://doi.org/10.22270/jddt.v2i1.70
33. Srinath P, Vyas SP, Diwan PV, Preparation and pharmacodynamic evaluation of liposomes of indomethacin, Drug Dev. Ind. Pharm., 2000; 26(3):313-321.
34. Taha EI, El-Anazi MH, El-Bagory IM, Bayomi MA, Design of liposomal colloidal systems for ocular delivery of ciprofloxacin, Saudi Pharm. J., 2014; 22:231-239.
35. Petrovic´S., Ana Tacˇic´ A., Savic´ S., Nikolic´ V., Nikolic´ L., Savic S., Sulfanilamide in solution and liposome vesicles; in vitro release and UV-stability studies, Saudi Pharm. J., 2017; 25:1194-1200.
36. Xu X, Khan MA, Burgess DJ, A quality by design (QbD) case study on liposomes containing hydrophilic API: I. Formulation processing design and risk management, Int. J. Pharm., 2011; 419:52-59.
37. Lee SC, Lee KE, Kim JJ, Lim SH, The effect of cholesterol in the liposome bilayer on the stabilization of incorporated Retinol, J. Liposome Res., 2005; 15:157-66.
38. Kirby C, Clarke J, Gregoriadis J, Effect of cholesterol content of small unilamellar liposomes on their stability in-vivo and in-vitro, Biochem. J., 1980; 186:591-598.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).